Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design

DOI10.1016/J.JECONOM.2018.12.009zbMATH Open1452.62816OpenAlexW3121524160MaRDI QIDQ2000854FDOQ2000854

Vahid Montazerhodjat, Andrew W. Lo, Leah Isakov

Publication date: 1 July 2019

Published in: Journal of Econometrics (Search for Journal in Brave)

Full work available at URL: https://doi.org/10.1016/j.jeconom.2018.12.009

Recommendations

• A Bayesian Approach to the Design of Phase II Clinical Trials
• Bayesian adaptive designs for clinical trials
• A Bayesian decision approach for sample size determination in phase II trials
• scientific article; zbMATH DE number 1984442
• scientific article; zbMATH DE number 1522737

zbMATH Keywords

clinical trial designadaptive designFDABayesian decision analysisdrug-approval process

Mathematics Subject Classification ID

Applications of statistics to biology and medical sciences; meta analysis (62P10) Bayesian problems; characterization of Bayes procedures (62C10)

Cites Work

• Title not available (Why is that?)
• Clinical Trials
• Bayesian statistics and the efficiency and ethics of clinical trials
• Title not available (Why is that?)
• Interim Analysis in Clinical Trials: The Role of the Likelihood Principle
• Bayesian Approaches to Randomized Trials
• Choosing sample size for a clinical trial using decision analysis

Cited In (1)

• Annals issue in honor of Jerry A. Hausman. Editors' introduction

This page was built for publication: Is the FDA too conservative or too aggressive?: a Bayesian decision analysis of clinical trial design

Report a bug (only for logged in users!)Click here to report a bug for this page (MaRDI item Q2000854)